B+
Bull case
25%
Probability
Target price
$1.80
Analysis reference price unavailable
Analysis 2026-06-22 · RankAlpha Sentiment Codex
CRDL
Cardiol TherapeuticsFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
The constructive case is that MAVERIC enrollment is advancing, Phase II data have gained peer-reviewed validation support, and the company says it is funded through completion of the pivotal trial, allowing investors to focus on the next clinical milestone rather than near-term survival financing [#PR-2026-04-01] [#PR-EARNINGS-2026-05-07].
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
CRD-38 is still an earlier-stage secondary program, so pipeline diversification is not yet strong enough to offset lead-program dependency.
Momentum
91
Value
41
Sentiment
4
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.95 · Bull $1.80 · Bear $0.50Analysis 2026-06-22; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-10 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-22 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-10
Investment thesis
As of 2026-09-10
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-10. Definitions
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $8.50
Why
Momentum91 · Δ7d -
Value41 · Δ7d -0.0
Sentiment4 · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Value remains the lead driver in the composite, 7D delta -0.0.
Contradictions & invalidation
- • CRD-38 is still an earlier-stage secondary program, so pipeline diversification is not yet strong enough to offset lead-program dependency.
- • Despite stated runway into Q4 2027, small-cap biotech financing risk can return quickly if timelines slip or capital-market conditions worsen.
- • The bear case is that CRDL remains a low-coverage, single-lead-program small-cap biotech where most equity value still rests on eventual Phase III success; enrollment progress and publication support do not resolve registrational, timing, or commercialization risk, and there is no robust post-print analyst-revision packet here to confirm a broader rerating.
Catalyst clock
2026-09-30
MAVERIC enrollment completion is the key near-term inflection
Lead driver: Value · See fundamentals
Momentum
91
9% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
+0.1
Sentiment
4
62% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 91.0 / Value 41.2 / Sentiment 3.7
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-06-22. Scenario method
Most likely
B
Base case
45%
Probability
Target price
$0.95
Analysis reference price unavailable
Analysis 2026-06-22 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-06-22 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$209.68M
Beta
0.84
Shares Out
116.82M
P/E (TTM) · Derived
-6.5
P/S (TTM)
-
P/FCF (TTM) · Derived
-10.35
Rev YoY
-100.0%
EPS YoY
-47.7%
Gross Margin
-
Op Margin
-
Net Debt
-$15.53M
Current Ratio
5.55
As of 2026-09-10 • Updated nightlySource: Internal modelMethods & Data